Comparative Pharmacology
Head-to-head clinical analysis: RETEVMO versus VITRAKVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RETEVMO versus VITRAKVI.
RETEVMO vs VITRAKVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRK) A, B, and C. It binds to the ATP-binding site of TRK kinases, preventing their activation and downstream signaling pathways, thereby inhibiting proliferation and inducing apoptosis in tumors with NTRK gene fusions.
160 mg orally twice daily
100 mg orally twice daily
None Documented
None Documented
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Terminal elimination half-life is approximately 16.2 hours (range 12-20 h) in patients; supports twice-daily dosing.
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Primarily hepatic metabolism, with 39% recovered in feces (36% as unchanged drug) and 18% in urine (0.5% unchanged).
Category C
Category C
Kinase Inhibitor
Kinase Inhibitor